Inhibition of the signalling kinase JAK3 alleviates inflammation in monoarthritic rats
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibition of the signalling kinase JAK3 alleviates inflammation in monoarthritic rats
Authors
Keywords
-
Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume 164, Issue 1, Pages 106-118
Publisher
Wiley
Online
2011-03-22
DOI
10.1111/j.1476-5381.2011.01353.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice
- (2010) Tsung H. Lin et al. ARTHRITIS AND RHEUMATISM
- Berberine ameliorates TNBS-induced colitis by inhibiting lipid peroxidation, enterobacterial growth and NF-κB activation
- (2010) In-Ah Lee et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Therapeutic potential of nucleic acid-binding isoquinoline alkaloids: Binding aspects and implications for drug design
- (2010) Kakali Bhadra et al. MEDICINAL RESEARCH REVIEWS
- NSC114792, a novel small molecule identified through structure-based computational database screening, selectively inhibits JAK3
- (2010) Byung-Hak Kim et al. Molecular Cancer
- Berberine suppresses proinflammatory responses through AMPK activation in macrophages
- (2009) Hyun Woo Jeong et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial
- (2009) J H Coombs et al. ANNALS OF THE RHEUMATIC DISEASES
- A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs
- (2009) Yiyi Sun et al. ANTI-CANCER DRUGS
- The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
- (2009) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Berberine-induced decline in circulating CD31+/CD42− microparticles is associated with improvement of endothelial function in humans
- (2009) Jie-mei Wang et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- Therapeutic potential of JAK2 inhibitors
- (2009) S. Verstovsek Hematology-American Society of Hematology Education Program
- Protective effects of berberine on radiation-induced lung injury via intercellular adhesion molecular-1 and transforming growth factor-beta-1 in patients with lung cancer
- (2008) Yunfang Liu et al. EUROPEAN JOURNAL OF CANCER
- The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia
- (2008) Elizabeth Kudlacz et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells
- (2008) D. B. Lipka et al. MOLECULAR CANCER THERAPEUTICS
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
- Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine
- (2008) Mohsen Imanshahidi et al. PHYTOTHERAPY RESEARCH
- Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis
- (2008) Anthony J Milici et al. ARTHRITIS RESEARCH & THERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More